Cellular angiofibroma of the vagina
A case report and literature review
Xia-Qin Cai, BDa, Xi-Gang Ye, BDb, Ya-Zhen Zhang, BDc, Zeng-Li Shen, MSd, Ke Hong, MSa, Shu-Zhi Zhang, MDe,*

1. Introduction
Cellular angiofibroma (CAF), a rare benign mesenchymal tumor, is histologically characterized by abundant thick-walled vessels with a spindle cell component.[1] CAF occurs in both men (referred to as “angiomyofibroblastoma like tumor”) and women (particularly in the vulva).[2] Due to its low incidence, articles pertaining to vulvar CAF in the published literature largely comprise of small case series or case reports.[2-14] Owing to the non-specific clinical manifestations of CAF, preoperative diagnosis is typically challenging. Pathological examination is required to confirm the diagnosis of the disease. According to a recent review, only a few cases of vaginal CAF have been reported.[14] Although the World Health Organization (WHO) has classified CAF as one of the female reproductive system tumors, its clinical and pathological features are not well characterized.[15] We report a case of vaginal CAF treated by surgery.

2. Case report
A 47-year-old woman presented for the removal of intrauterine device on October 28, 2021, as she had achieved menopause one year back. The patient had no discomfort or awareness of any mass in her vagina. She has history of breast cancer and papillary thyroid cancer. Till date, no progression of thyroid cancer or breast cancer has been observed. Her menstrual cycle was regular, and she had one child delivered vaginally.

Written informed consent of the patient has been obtained for publication of this case report.

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical approval for this study was obtained from an ethics committee of Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China. *Correspondence: Shu-Zhi Zhang, Hangzhou Medical College, 182 Tianmushan Road, Hangzhou, Zhejiang, China (e-mail: 1059317385@qq.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Cai X-Q, Ye X-G, Zhang Y-Z, Shen Z-L, Hong K, Zhang S-Z. Cellular angiofibroma of the vagina: A case report and literature review. Medicine 2022;101:35(e30293).}

The patient is a teacher. She has undergone an annual gynecological physical examination. However, no vaginal tumor was found by other physicians. The CAF tumor was found in time during gynecological examination before the removal of the intrauterine device. The patient was very satisfied with the early diagnosis and therapeutic effect.

Antibiotics (intravenous cefuroxime sodium 0.75 g bid for 1 day) were administered to prevent infection. The patient showed no signs of recurrence at one-month follow-up.

Conclusion: In summary, CAF is a rare benign soft tissue tumor. Surgery is the only treatment method, and the definitive diagnosis of CAF is based on histopathological examination of surgical specimen. Long-term follow-up is needed for surveillance of recurrence.

Abbreviations: AAM = the invasive angiomyxoma, AMF = angiomyofibroblastoma, CAF = cellular angiofibroma, NILM = negative intraepithelial lesion or malignancy, TCT = Thinprep cytologic test, Vim = vimentin, WHO = World Health Organization.

Keywords: case report, cellular angiofibroma, immunohistochemistry, pathology, vagina

Received: 7 May 2022 / Received in final form: 14 June 2022 / Accepted: 18 July 2022
http://dx.doi.org/10.1097/MD.0000000000030293
She was diagnosed with invasive breast cancer in right breast and had undergone breast preservation surgery plus axillary dissection on February 2, 2016. The size of the excised tumor was 0.8 × 0.6 × 1.8 cm. The subsequent systematic therapy included 29 cycles of postoperative radiotherapy and 6 cycles of chemotherapy. She has continued to receive tamoxifen and has been regularly followed-up at the Shanghai Fudan University Cancer Hospital for more than 5 years since the operation. There was no recurrence of breast cancer. The patient also underwent a thyroid biopsy on May 17, 2017, due to long-standing thyroid nodules for 30 years. The histopathological diagnosis was papillary thyroid cancer. She underwent surgery for the removal of unilateral thyroid gland on August 22, 2020. She was then prescribed levothyroxine tablet (50 µg) once daily. Till date, no recurrence of breast cancer. The patient also underwent a 29 cycles of postoperative radiotherapy and 6 cycles of chemotherapy. She has continued to receive tamoxifen and has been regularly followed-up at the Shanghai Fudan University Cancer Hospital for more than 5 years since the operation. There was no recurrence of breast cancer. The patient also underwent a thyroid biopsy on May 17, 2017, due to long-standing thyroid nodules for 30 years. The histopathological diagnosis was papillary thyroid cancer. She underwent surgery for the removal of unilateral thyroid gland on August 22, 2020. She was then prescribed levothyroxine tablet (50 µg) once daily. Till date, no recurrence of breast cancer.

6. Discussion

CAF was first described by Nucci et al[16] in the vulva of middle-aged women in 1997. CAF mainly occurs in the vulva-vaginal area of women with the clinical manifestations of asymptomatic, slowly-growing soft tissue masses, sometimes accompanied by mild pain and discomfort. In the published literature, most articles pertaining to vaginal CAF are case reports or small case series.[14,17–22] Our patient had a well-defined solid and round mass with a maximum length of 2.5 cm, which was consistent with the previously reported cases.

The cause of CAF is still unclear. Lane et al mentioned that long-term use of estrogen therapy may be related to the occurrence of CAF.[10] According to Laskin et al, the extravasation of red blood cells and formation of micro-thrombi in tumors are related to hemodynamic changes. In other words, the tumor cells may originate from differentiation of stem cells around the vascular endothelium into muscle fibers.[17] Our patient had received tamoxifen for more than 5 years after breast cancer surgery. Therefore, it is possible that CAF occurred due to her use of estrogen and was hormone-dependent, which is consistent with related literature reports.

Because vaginal CAFs are less frequent than vulvar CAFs and there are no specific clinical manifestations or signs, it is liable to be misdiagnosed as other vaginal diseases before surgery. For example, in the present case, the lesion was misdiagnosed as a vaginal wall cyst by pelvic examination. In addition, preoperative ultrasound examination did not reveal any vaginal mass, which may be due to the relatively small size of the tumor and the low sensitivity of ultrasound for detection of...
pelvic mass. Besides, MRI was not performed because of the intrauterine contraceptive device. Therefore, in practice, it is difficult to diagnose this lesion based on preoperative imaging examination.

The definitive diagnosis of CAF can only be made by pathological examination of surgical specimen. Microscopically, the CAF tumor tissues are composed of spindle stromal cells and abundant blood vessels.[14,20] The density of the CAF tumor cells is not uniform, and the cells have small nucleus with rare mitotic figures; large multinucleated cells may be seen occasionally. In addition, CAF is rich in small and medium-size blood vessels with thickened and hyaline walls and the interstitium has scattered collagen cellulose of varying thickness, which may show myxoid degeneration and edema.[18] Immunohistochemistry findings are important for the diagnosis of CAF.[18] CAF tumor cells exhibit diffusive and strong positivity for VIM, diffusive positivity for CD34, partial positivity for smooth actin (SMA), and negativity for Desmin (S-100).[24] The pathological features and immunohistochemistry of the present case were consistent with previous reports.

In the majority of the reported CAF cases, there was no recurrence after local simple resection. However, Mc Cluggage et al reported a case of recurrence after resection with negative margins, and Tang et al reported a case of suspected CAF recurrence.[11,25] Therefore, patients with CAF require long-term follow-up after surgery.

Several tumors need to be considered in the differential diagnosis of CAF. First is the invasive angiomyxoma (AAM). AAM is a malignant tumor with large size (usually >5 cm in diameter) located mainly in the pelvic cavity.[26] The boundary of AAM is not well demarcated, and it shows infiltrative growth; moreover, it shows a tendency for recurrence after local excision. On pathological examination, the tumor cells are sparse, and the mucous interstitium is diffuse. In addition, AAM tumor cells are small, uniformly distributed monomorphic spindle-shaped orstellate cells scattered in the lesion, forming good smooth muscle-like cells.[26] On the contrary, CAF is a benign tumor with small size (generally <3 cm in diameter), shallow in site, and typically does not recur after surgical resection. AAM is typically positive for vimentin and myosin, while CAF is typically diffusively and strongly positive for vimentin (Vim), CD34(+), and S-100 (-). Another tumor that may mimic CAF is vaginal angiomyofibroblastoma. AMF shows a clear boundary under the microscope, with large parenchymal blood vessels of variable sizes, distributed in clusters, and diversified tumor cells and nuclei. In addition, the myofibroblasts are unevenly distributed, with densely packed areas of multiple cells alternating with regions of low cellular density. However, the tumor cells in the dense area show perivascular arrangement, which are distributed in the myxematous interstitium, with no cellular atypia.[19,27] Under high magnification, there is extensive distribution of collagen fibers between the tumor cells. Besides, the hypocellular areas show mucin- edema-like background and the cells are long fusiform with slender cytoplasm, deeply stained nuclei, and no mitoses.[28]

On immunohistochemistry examination, AMF cells are typically diffusely and strongly positive for sarcomeric protein, but negative for CD34, S-100 cytokeratin, and epithelial membrane antigen.[23] Last but not the least, is the vaginal solitary fibrous tumor, which is composed of spindle cells and abundant blood vessels, and the immune tissue marker CD34 is always positive.[29,30] On the contrary, CAF tumor cells exhibit diffusive and strong positivity for VIM, diffusive positivity for CD34, partial positivity for smooth actin (SMA), negativity for Desmin (S-100).[24] Owing to the rarity of CAF, the present case report adds value to the contemporary literature by describing the clinicopathological characteristics of this disease. However, the short follow-up period in this case report is a limitation.

7. Conclusion

In summary, CAF is a rare benign soft tissue tumor, which is difficult to diagnose before surgery. Surgery is the only treatment method, and definitive diagnosis of CAF is made by histopathological examination of surgical specimen. Long-term follow-up is needed for surveillance of recurrence.

Author contributions
Conceptualization: Zeng-Li Shen, Ya-Zhen Zhang.
Investigation: Xia-Qin Cai, Xi-Gang Ye, Ke Hong.
Supervision: Shu-Zhi Zhang.
Validation: Shu-Zhi Zhang, Xia-Qin Cai.
Visualization: Zeng-Li Shen.
Writing – original draft: Xia-Qin Cai, Zeng-Li, Ke Hong. Shu-Zhi Zhang.
Writing – review & editing: Xia-Qin Cai, Ke Hong.

References
[1] Mandato VD, Santagisi S, Cavazza A, et al. Cellular angiofibroma in women: a review of the literature. Diagn Pathol. 2015;10:114.
[2] Santiago D, Perlman B, Lespinasse P, et al. Massive cellular angiofibroma of the vulva. J Low Genit Tract Dis. 2017;21:e28–9.
[3] Ahmadna H, Kamalati A, Dolati M, et al. Angiomyofibroma of the vulva. J Cutan Med Surg. 2014;18:203–5.
[4] Aydin U, Terzi H, Turkay U, et al. A giant vulvar mass: a case study of cellular angiofibroma. Case Rep Obstet Gynecol. 2016;2016:2094818.
[5] Colombat M, Liard-Meunier M, Sevestre H, et al. eds. Cellular angiofibroma. A rare vulvar tumor. Report of a case. Ann Pathol. 2001;21:145–8.
[6] Dargent JL, de Saint Aubain N, Galdón MG, et al. Cellular angiofibroma of the vulva: a clinicopathological study of two cases with documentation of some unusual features and review of the literature. J Cutan Pathol. 2003;30:405–11.
[7] Fachada AHB, Pais C, Fernandes MAE, et al. Cellular angiofibroma: a rare vulvar tumor case report. Rev Bras Ginecol Obstet. 2020;42:365–8.
[8] Kerkuta R, Kennedy CM, Renda JA, et al. Vulvar cellular angiofibroma: a case report. Am J Obstet Gynecol. 2005;193:1750–2.
[9] Khmou M, Lamalini M, Mahily A, et al. Cellular angiofibroma of the vulva: a poorly known entity, a case report and literature review. BMC Clin Pathol. 2016;16:8.
[10] Lane JF, Walker AN, Mullah EN J, et al. Cellular angiofibroma of the vulva. Gynecol Oncol. 2001;81:326–9.
[11] McCluggage WG, Pereney M, Irwin ST. Recurrent cellular angiofibroma of the vulva. J Clin Pathol. 2002;55:477–9.
[12] McCluggage WG, Ganesan R, Hirschowitz I, et al. Cellular angiofibroma and related fibromatoses of the vulva: report of a series of cases with a morphological spectrum wider than previously described. Histopathology. 2004;45:380–8.
[13] Priyadarshi V, Sehgal N, Gupta SK, et al. Cellular angiofibroma: two case reports of a rare vulvar tumor. J Obstet Gynaecol India. 2014;64:65–7.
[14] Van Mulders S, Faes E, Broeckx G, et al. Cervicovaginal cellular angiofibroma. BMJ Case Rep. 2020;13:e235241.
[15] Fletcher CD, Unni K, Mertens F. World Health Organization classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone: Lyon, France: IARC press; 2002.
[16] Nucci MR, Granter SR, Fletcher CD. Cellular angiofibroma: a benign neoplasm distinct from angiomyofibroblastoma and spindle cell lipoma. Am J Surg Pathol. 1997;21:1636–44.
[17] Laskin WB, Fetsch JF, Tavassoli FA. Angiomyofibroblastoma of the female genital tract: analysis of 17 cases including a lipomatous variant. Hum Pathol. 1997;28:1046–55.
[18] Cheng D, Shuice L, Yue Q, et al. The clinical and pathological features of cellular angiofibroma [Chinese]. J Mod Oncol. 2015;23:2831–5.
[19] Ma JH, Qi X, Zhang P. A case of vaginal angiomyofibroblastoma and literature review [Chinese]. J Clin Pathol. 2005;18:1354–5.
[20] Arega C, Girma W, Sanchez Diaz JM. Angiomyofibroblastoma of the vulva and vagina. Mod Pathol. 1996;9:284–91.
[23] Song Z, Yue Q, Shuice L, et al. The clinical and pathological features of angiomyofibroblastoma: an analysis of 27 cases [Chinese]. J Mod Oncol. 2015;23:1121–5.

[24] Iwasa Y, Fletcher CD. Cellular angiofibroma: clinicopathologic and immunohistochemical analysis of 51 cases. Am J Surg Pathol. 2004;28:1426–35.

[25] Tang T, Fang LD. Clinicopathological analysis of 6 cases of fibroblast-myofibroblastic tumors [Chinese]. Chin J Clin Oncol. 2003;30:645–7.

[26] Chen H, Zhao H, Xie Y, et al. Clinicopathological features and differential diagnosis of aggressive angiomyxoma of the female pelvis: 5 case reports and literature review. Medicine (Baltim). 2017;96:e6820.

[27] Varras M, Akrivis C, Demou A, et al. Angiomyofibroblastoma of the vagina in a postmenopausal breast cancer patient treated with tamoxifen: clinicopathologic analysis of a case and review of the literature. Int J Gynecol Cancer. 2006;16:581–5.

[28] Ni SS, Xu XR, Li F. Clinical analysis of 4 cases of vaginal angiomyofibroblastoma [Chinese]. Zhejiang Med J. 2016;18:1534–6.

[29] Iyengar P, Ismiil ND, Gerber D, et al. Vaginal solitary fibrous tumor: a case report with recurrence after incomplete excision. J Low Genit Tract Dis. 2007;11:50–4.

[30] Placide N, Robert S. Solitary fibrous tumor of the vagina: a case report with review of the literature. Int J Surg Pathol. 2012;20:101–4.